Share

ASH presentations in San Diego

EORTC will be presenting four posters at the American Society of Hematology’s 58th Annual Meeting and Exposition (December 3-6, 2016) in San Diego

Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia (Abstract: 2775)

Session 612: Acute Lymphoblastic Leukemia: Clinical Studies: Poster II; Sunday 04.12.2016 – 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Hall GH

Authors: Caroline Piette, Stefan Suciu, Yves Bertrand, Anne Uyttebroeck, Els Vandecruys, Geneviève Plat, Patrick Lutz, Claire Pluchart, Nicolas Sirvent, Maryline Poirée, Pauline Simon, Alina Ferster, Claire Hoyoux, Francoise Mazingue, Robert Paulus, Dominique Plantaz, Caroline Thomas, Caroline Gilotay, Jutte Van Der Werff Ten Bosch, Pierre Simon Rohrlich, Yves Benoit


Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials (Abstract: 2847)

Session 617: Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II; Sunday 04.12.2016 – 6:00 PM – 8:00 PM
Location: San Diego Convention Center, Hall GH

Authors: Frédéric Baron*, Marian Stevens-Kroef*, Giovanna Meloni, Petra Muus, Jean-Pierre Marie, Constantijn J.M. Halkes, Xavier Thomas, Radovan Vrhovac, Giorgina Specchia, François Lefrère Sr, Simona Sica, Marco Mancini, Adriano Venditti, Anne Hagemeijer, Joop Jansen, Sergio Amadori, Theo de Witte, Roel Willemze, Stefan Suciu
* Co first authors


Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (Abstract: 2288)

Session 732: Clinical Allogeneic Transplantation: Results: Poster I; Saturday 03.12.2016 – 5:30 PM – 7:30 PM
Location: San Diego Convention Center, Hall GH

Authors: F. Baron, F. Efficace, L. Cannella, F. Mandelli, R.Willemze, P.Muus, J-P. Marie, D. Ferrero, M. Dictus, P. Fazi, E. La Sala, J-H. Bourhis, F. Fabbiano, A. Bosi, M. Sborgia, G., Martinelli, D. Bron, M. C. Petti, C. J.M. Halkes, W. J.F.M. van der Velden, M. Boccadoro, S. Amadori, R. A. Zittoun and S. Suciu


Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study (Abstract 1743)

Session 618: Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I; Saturday 03.12.2016 — 5:30 PM – 7:30 PM
Location: San Diego Convention Center, Hall GH
Authors: Laura Clement, Stefan Suciu, Isabelle Luquet, Alina Ferster, Karima Yakouben, Anne Uytterbroeck, Catherine Paillard, Nicolas Sirvent, Vitor Costa, Barbara De Moerloose, Francoise Mazingue, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Caroline Piette, Frank Speleman, Hélène Cavé, Jutte VanderWerff-tenBossch, Pierre Simon Rohrlich, Yves Bertrand, Yves Benoit, Geneviève Plat

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival